THE RECOVERY PEPTIDES
BPC-157 Explained — What It Is, What the Research Shows, and How It Is Used
By G1 Peptides · Medically reviewed by the G1 Peptides clinical team · Updated September 24, 2026 · 2 min read
THE SHORT ANSWER
BPC-157 is a 15-amino-acid fragment of a protective protein found in gastric juice. Two decades of animal studies show accelerated healing of tendon, ligament, muscle, and gut injury, largely through effects on blood-vessel growth and growth-factor signalling. Formal human trials are limited, so its use is based on that preclinical record plus clinical experience. It is dosed at 200–500 mcg once or twice daily by subcutaneous injection.
Origin
BPC stands for "Body Protection Compound." The parent protein was identified in human gastric juice; BPC-157 is a stable 15-amino-acid segment of it, synthesized for research. Its stability is unusual — it survives stomach acid — which is why it was first studied for gut protection and why oral forms exist alongside the injectable.
What the animal research shows
The literature is large — several hundred papers, most from a single group in Zagreb led by Predrag Sikirić — and consistent in direction:
- Gut: protection and healing of stomach ulcers, inflammatory bowel models, and fistulas; counteraction of NSAID damage (Sikiric 2011).
- Tendon and ligament: faster healing of transected Achilles tendon and medial collateral ligament in rats, with tendon cells showing increased outgrowth, survival, and migration in culture (Chang 2011).
- Muscle: improved recovery after crush and transection injuries, including functional recovery.
- Blood vessels: increased expression of VEGFR2 and nitric-oxide signalling — the likely common mechanism, since healing in poorly vascularized tissue like tendon depends on new blood supply.
- Safety: no toxicity identified across dose ranges far above those used in people, in multiple species.
The consistency across tissues is the appeal. The caveat is the source: the majority of the evidence comes from one laboratory, and independent replication is thinner than the paper count suggests.
What the human research shows
Very little formal data. A phase 1 safety study found no adverse effects, and an early trial in inflammatory bowel disease reported none, but there is no controlled human trial of BPC-157 for tendon, ligament, or muscle injury. Its clinical use rests on the preclinical record, the safety profile, and accumulated provider experience — which is real but not the same as trial evidence. A good provider will say so.
How it is used
- Dose: 200–500 mcg per injection, once or twice daily, is the range most protocols use. Some scale by body weight (roughly 2–4 mcg/kg).
- Route: subcutaneous injection, abdomen or near the injury. Oral capsules are used for gut-focused goals.
- Duration: four to eight weeks for an acute injury; longer courses for chronic issues, with reassessment.
- Pairing: very often with TB-500 — the Wolverine blend — because the two are studied for complementary mechanisms.
A 5 mg vial reconstituted in 2 mL is 2,500 mcg/mL; 250 mcg is 10 units and the vial holds 20 doses. The BPC-157 calculator converts any dose.
Safety
No consistent side effects beyond injection-site reactions have been reported in animals or in the limited human data. Two precautions providers apply: it is avoided in active cancer because it promotes blood-vessel growth, and it is not used in pregnancy for lack of data. It is prohibited by WADA for tested athletes.
Next: TB-500 explained.
FREQUENTLY ASKED
Is BPC-157 FDA-approved?
No. It has not been through FDA trials for any indication. It is available as a compounded prescription where pharmacy regulations permit, which changes over time — G1's catalog reflects what licensed pharmacies can currently make.
Should I inject it near the injury?
Some providers prefer injecting subcutaneously close to the affected area; others use the abdomen. Both reach systemic circulation, and animal data shows effects on distant injuries from systemic dosing. Follow your provider's instruction.
How long is a typical course?
Four to eight weeks is common for an acute injury, sometimes longer for chronic tendon or gut issues, with a reassessment at the end. Your provider sets the duration.
SOURCES
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 — novel therapy in gastrointestinal tract. Current Pharmaceutical Design (2011)
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology (2011)
This article is educational and is not medical advice. Peptides are prescription medications; whether any of them is appropriate for you is a decision for a licensed provider who knows your history.